0000950142-17-001798.txt : 20171003
0000950142-17-001798.hdr.sgml : 20171003
20171003174207
ACCESSION NUMBER: 0000950142-17-001798
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171003
FILED AS OF DATE: 20171003
DATE AS OF CHANGE: 20171003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wygant Jonathan
CENTRAL INDEX KEY: 0001584145
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16789
FILM NUMBER: 171119485
MAIL ADDRESS:
STREET 1: 3750 TORREY VIEW COURT
CITY: SAN DIEGO
STATE: X1
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALERE INC.
CENTRAL INDEX KEY: 0001145460
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 043565120
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 51 SAWYER ROAD
STREET 2: SUITE 200
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7816473900
MAIL ADDRESS:
STREET 1: 51 SAWYER ROAD
STREET 2: SUITE 200
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: INVERNESS MEDICAL INNOVATIONS INC
DATE OF NAME CHANGE: 20010720
4
1
es1701022_4-wygant.xml
OWNERSHIP DOCUMENT
X0306
4
2017-10-03
1
0001145460
ALERE INC.
ALR
0001584145
Wygant Jonathan
51 SAWYER ROAD
SUITE 200
WALTHAM
MA
02453
0
1
0
0
VP, Controller, CAO
Common Stock
2017-10-03
4
D
0
1909
D
0
D
Restricted Stock Units
2017-10-03
4
D
0
6666
D
Common Stock
6666
0
D
Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
/s/ Doug Barry, Attorney-in-Fact
2017-10-03